Table 1.
| Study | Population | Intervention | Results with SGLT2i |
|---|---|---|---|
| Fructuoso et al., 2023 (14). | Observational, n= 339 KTR with T2DM or PTDM |
Significant reductions in body weight, BP, fasting glycaemia, HbA1c, UPCR. The most frequent adverse event was UTI in 14%. |
|
| Rajasekeran et al., 2017 (15) | Case series (4 SPKT, 6 KTR) KTR or SPKT on canagliflozin |
Canagliflozin | Reduction of HbA1c −0.84% Reduction of body weight −2.14 kg Reduction of BP −6.4mmHg No UTI or mycotic infection |
| AlKindi et al., 2020 (16). | Case series (8 KTR) KTR on SGLT2i (T2DM or PTDM) |
Empagliflozin (6 patients), dapagliflozine (2 patients) | -6 months follow-up: Decrease in body weight -4kg -12 months follow-up: Decrease of HbA1c Stable eGFR Stable BP One episode of UTI |
| Attallah and Yassine 2019 (17) | Case series (8 KTR) KTR on empagliflozin (T2DM or PTDM) |
Empagliflozin | -12 months follow-up: Reduction of HbA1c Slight reduction in eGFR, then stabilized Reduction of proteinuria (UPCR) of 0.6 g/day. Reduction of body weight - 2.4 kg. Two cases of UTI |
| Schwaiger et al., 2019 (18) | Prospective interventional study (14 KTR) KTR with insulin |
Empagliflozin | -4 weeks follow-up: Reduction of eGFR by 7.5 ml/min/1.73 m2. Three cases of UTI and one case of uncomplicated balanitis. -12 months follow-up: Stable HbA1c. Reduction of body weight -1.6 kg |
| Mahling et al., 2019 (19) | Prospective case series (10 KTR) Stable KTR |
Empagliflozin | -12 months follow-up: No change in eGFR Reduction of body weight −1.9 kg Low rate of UTI and other side effects |
| Shah et al., 2019 (20) | Prospective descriptive study (24 KTR) Stable KTR with T2DM or PTDM |
Canagliflozin | -6 months follow-up: Decrease of body weight -2.5kg Decrease of: SBP -8mmHg, DBP -2mmHg HbA1c reduction -0.9% No UTI increase |
| Song et al., 2020 (21) | Observational retrospective (50 KTR) KTR, eGFR >30 ml/min/1.73 m2 with T2DM or PTDM |
Empagliflozin (n = 43), canagliflozin (n = 6) or dapagliflozin (n = 1) | -6 months follow-up: Decrease of body weight −2.95 kg No increase of UTI Stable renal function |
| Lim et al., 2022 (22) | Observational retrospective (226 KTR) KTR with T2DM on SGLT2i |
Lower risk for all-cause mortality, death-censored graft failure and serum creatinine doubling eGFR stable |
|
| Lemke et al., 2022 (23) | Observational retrospective (39 KTR) KTR on SGLT2i (T2DM or PTDM) |
Canagliflozin (n = 12), dapagliflozin (n = 3), empagliflozin (n = 24) | -12 months follow-up: Stable renal function UTI was the most common adverse event HbA1c reduction -1% |
AKI, acute kidney injury; BP, Blood Pressure; DBP, diastolic blood pressure; eGFR, estimated Glomerular Filtration Rate; RCT, Randomized Control Trial; KTR, kidney transplant recipient; SBP, systolic blood pressure; PTDM, Post Transplant Diabetes Mellitus; SPKT, Simultaneous pancreas-kidney transplantation; UPCR, Urine Protein Creatinine Ratio; UACR, Urine Albumin creatinine Ratio; UTI, Urinary Tract infection.